同型半胱氨酸、叶酸和尿酸在认知功能障碍诊断中的意义

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1340 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the significance of homocysteine, folic acid and uric acid in diagnosis of cognitive dysfunction. Methods: We selected 63 patients with Alzheimer’s disease (AD), 56 patients with vascular dementia (VaD), 40 patients with mild cognitive impairment (MIC), and 45 healthy individuals at same period as control. The levels of homocysteine, folic acid and uric acid were detected in each group. Results: ①The levels of homocysteine in AD group and VaD group were higher than those in MCI group and control group; ②The levels of folic acid in AD group, VaD group, MCI group were lower than those in control group; ③The levels of uric acid in AD group were lower than those in VaD group, MCI group and control group. Conclusion: High levels of homocysteine may be related with the pathogenesis of cognitive dysfunction. Lower levels of folic acid are related with the cognitive dysfunction. The AD patients has lower levels of uric acid. Detecting homocysteine, folic acid and combinated with uric acid is helpful for the diagnosis of cognitive dysfunction.

Key words： homocysteine folic acid uric acid Alzheimer’s disease vascular dementia mild cognitive impairment

Received: 21 November 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Tianying
	ZHANG Xiong
	ZHENG Yongke
	WANG Yidong
	PAN Jing
	CHEN Yan.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2015/V45/I8/608

[1] Song Y, Wang J. Overview of Chinese research on senile dementia in mainland China[J]. Ageing Res Rev, 2010, 9(1): 6-12.
[2] Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria[J]. Lancet Neurol, 2007, 6(8): 734-746.
[3] Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop[J]. Neurology, 1993, 43(2): 250-260.
[4] Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairent[J]. J Intern Med, 2004, 256(3): 240-246.
[5] Oulhaj A, Refsum H, Beaumont H, et al. Homocysteine as a predictor of cognitive decline in Alzheimer′s disease[J]. Geriatr Psychiatry, 2010, 25(1): 82-90.
[6] Serot J, Barbe F, Arming E, et al. Homocysteine and methyl-malonic acid concentration in cerebrospinal fluid: relation with age and Alzheimer’s disease[J]. J Neurol Neurosurg Psychiatry, 2005, 76(11): 1585-1587.
[7] Mirashi EH, Jacobsen DW, Debanne SM, et al. Plasma total homocysteine levels, dietary vitamin B6 and folate intake in AD and healthy aging[J].J Nutr Health Aging, 2003, 7(3): 160-165.
[8] Ferreccio C, Rollán A, Harris PR, et al. Gasrric cancer is related to early Helicobacer pylori infection in a high-prevalence country[J]. Cancer Epidemiol Bionmarkers Prev, 2007, 16(4): 662-667.
[9] 胡丹, 何志勇, 王小同, 等. 血浆同型半胱氨酸水平与脑梗死近期复发关系的临床研究[J]. 温州医学院学报, 2010,40(4): 371-373.
[10] 宋君如, 张怀安, 葛成东. 高同型半胱氨酸与阿尔茨海默病关系探讨[J]. 吉林医学, 2012, 33(34): 7431-7432.
[11] Mansoori N, Tripathi M, Alam R, et al. Serum folic acid and RFC A80G polymorphism in Alzheimer’s disease and vascular dementia[J]. Am J Alzheimer’s Dis Other Demen, 2014, 29(1): 38-44.
[12] Cacciapuoti F. Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer’s disease[J]. J Thromb Thrombolysis, 2013, 36(3): 258-262.
[13] Morris MS. Homocysteine and Alzheimer’s disease[J]. Lancet Neurol, 2003, 2(7): 425-428.
[14] Corrada MM, Kawas CH, Hallfrisch J, et al. Reduced risk of Alzheimer’s disease with high folate intake: the Baltimore Longitudinal Study of Aging[J]. Alzheimers Dement, 2005, 1(1): 11-18.
[15] Ravaglia G, Forti P, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease[J]. Am J Clin Nutr, 2005, 82(3): 636-643.
[16] Sachdev PS. Alzheimer disease: homocysteine and alzheimer disease: an intervention study[J]. Nat Rev Neurol, 2011, 7(1): 9-10.
[17] Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer’s disease and subcortical vascular dementia[J]. J Neurol Neurosurg Psychiatry, 2004, 75(1): 61-71.
[18] Zuliani G, Cavalieri M, Galvani M, et al. Markers of endothelial dysfunction in older subjects with late onset Alzheimer’s disease or vascular dementia[J]. Neurol Sci, 2008,272(1-2): 164-170.
[19] Bennett S, Grant MM, Aldred S. Oxidative stress in vascular dementia and Alzheimer’s disease: a common pathology[J]. Alzheimers Dis, 2009, 17(2): 245-257.
[20] He K, Merchant A, Rimm EB, et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men[J]. Stroke, 2004, 35(1): 169-174.
[21] Li Q, Yang Z, Lu B, et al. Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes[J]. Cardiovasc Diabetol, 2011, 10(1): 72.
[22] Mottillo S, Fillion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and metaanalysis[J]. Am Coll Cardiol, 2010, 56(14): 1113-1132.
[23] Cankurtaran M, Yesil Y, Kuyumcu ME, et al. Altered levels of homocysteine and serum natural antioxdants links oxidative damage to Alzheimer’s disease[J]. J Alzheimers Dis, 2013, 33(4): 1051-1058.
[24] Kawamoto R, Tabara Y, Kohara K, et al. Synergistic influence of age and serum uric acid on blood presure among community-dwelling Japanese women[J]. Hypertens Res, 2013, 36(7): 634-638.
[25] Chen X, Guo X, Huang R, et al. Serum uric acid levels in patients with Alzheimer’s disease: a meta-analysis[J]. Plos One, 2014, 9(4): e94084.
[26] Polidori MC, Mattioli P, Aldred S, et al. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia[J]. Dement Geriatr Cogn Disord, 2004, 18(3-4): 265-270.
[27] Rinaldi P, Polidori MC, Metastasio A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease[J]. Neurobiol Aging, 2003, 24(7): 915-919.